Wiley Blackwell

SHERPA: Unknown

People

  1. Vickers
    Vickers
  2. Horwitz
    Horwitz
  3. Panageas
    Panageas
  4. Kingham
    Kingham
  5. Halpern
    Halpern
  6. Sklar
    Sklar
  7. Begg
    Begg
  8. Offit
    Offit
  9. Robson
    Robson
  10. Korc-Grodzicki
    Korc-Grodzicki

Groups

  1. Population Sciences Research Program (614)
  2. Survivorship Research (317)
  3. Department of Medicine (280)
  4. Epidemiology and Biostatistics (280)
  5. Surgery (198)
  6. Solid Tumor Oncology Division (160)
  7. Health Outcomes Research Group (138)
  8. Biostatistics Service (135)
  9. Psychiatry and Behavioral Sciences, Department of (115)
  10. Division of Subspecialty Medicine (105)
Search Within
  1. "Population Sciences Research Program"
Formats
  1. Journal Article (474)
  2. Meeting Abstract (93)
  3. Review (14)
  4. Editorial (12)
  5. Correspondence (6)
  6. Research Letter (5)
  7. Book Section (4)
  8. Conference Paper (3)
  9. Guidelines (3)
Groups
  1. Population Sciences Research Program (614)
  2. Survivorship Research (317)
  3. Department of Medicine (280)
  4. Epidemiology and Biostatistics (280)
  5. Surgery (198)
  6. Solid Tumor Oncology Division (160)

More Groups

People
  1. Andrew Vickers (69)
  2. Steven Horwitz (55)
  3. Katherine Panageas (38)
  4. T Peter Kingham (37)
  5. Allan Halpern (31)
  6. Charles Sklar (31)

More People

Years
  1. 2025 (12)
  2. 2024 (34)
  3. 2023 (38)
  4. 2022 (37)
  5. 2021 (36)
  6. 2020 (33)

More Years

Publications
  1. Cancer (240)
  2. BJU International (66)
  3. Journal of Surgical Oncology (43)
  4. Hematological Oncology (38)
  5. Journal of the American Geriatrics Society (35)
  6. Cancer Medicine (31)

More Publications

Results (614)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Response to brentuximab vedotin by CD30 expression: Results from five trials in PTCL, CTCL, and B‐cell lymphomas
    Meeting Abstract

    Jagadeesh, D.; Horwitz, S.; Bartlett, N. L.; Advani, R.; Jacobsen, E.; Duvic, M.; Gautman, A.; Rao, S.; Onsum, M.; Fanale, M.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Response to A+CHP by CD30 expression in the ECHELON‐2 trial
    Meeting Abstract

    Illidge, T.; Horwitz, S.; Iyer, S.; Bartlett, N.; Kim, W.; Tilly, H.; Belada, D.; Feldman, T.; Illés, Á; Jacobsen, E.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Anaplastic large cell lymphoma, ALK‐negative: Analysis of 235 cases collected by the T‐cell project
    Meeting Abstract

    Shustov, A.; Cabrera, M.; Bellei, M.; Civallero, M.; Ko, Y. H.; Manni, M.; Horwitz, S. M.; Antonio De Souza, C.; Radford, J.; Varela, S. B.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Final data from the phase 3 ALCANZA study: Brentuximab vedotin (BV) vs physician's choice (PC) in patients (PTS) with CD30‐positive (CD30+) cutaneous T‐cell lymphoma (CTCL)
    Meeting Abstract

    Horwitz, S. M.; Scarisbrick, J.; Prince, H. M.; Whittaker, S.; Duvic, M.; Kim, Y. H.; Quaglino, P.; Zinzani, P. L.; Bechter, O.; Eradat, H.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Phase I/II study of CHOEP plus lenalidomide as initial therapy for patients with stage II‐IV peripheral T‐cell lymphoma: Phase II results
    Meeting Abstract

    Lunning, M.; Horwitz, S.; Advani, R.; Vose, J.; Lee, H.; Mehta‐Shah, N.; Zain, J.; Haverkos, B.; Lechowicz, M.; Moskowitz, A.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Incidence and treatment outcomes of patients with transformed marginal zone lymphoma treated with RCHOP‐like regimens
    Meeting Abstract

    Rajeeve, S.; Bobillo, S. V.; Zelenetz, A. D.; Straus, D. J.; Palomba, M. L.; Noy, A.; Horwitz, S. M.; Moskowitz, A. J.; Hamlin, P. A.; Matasar, M. J.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Clinical characteristics and outcomes of stage I diffuse large B cell lymphoma (DLBCL) in the rituximab‐era
    Meeting Abstract

    Bobillo, S.; Joffe, E.; Lavery, J.; Noy, A.; Palomba, L.; Straus, D. J.; Kumar, A.; Batlevi, C.; Horwitz, S.; Moskowitz, A.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Impact of pet imaging and histologic transformation on the prognosis of early disease progression in follicular lymphoma
    Meeting Abstract

    Batlevi, C. L.; Sha, F.; Alperovich, A.; Ni, A.; Smith, K.; Ying, Z.; Hamlin, P.; Horwitz, S. M.; Kumar, A.; Matasar, M.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Analysis of clinical determinants driving safety and efficacy of camidanlumab tesirine (ADCT‐301, Cami) in relapsed/refractory (R/R) classical Hodgkin lymphoma (CHL)
    Meeting Abstract

    Collins, G.; Horwitz, S.; Hamadani, M.; Samaniego, F.; Spira, A.; Caimi, P.; Davies, A.; Menne, T.; Fields, P.; Cruz, H.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Risk of breast implant associated anaplastic large cell lymphoma (BIA‐ALCL) in a cohort of 3546 women prospectively followed after receiving textured breast implants
    Meeting Abstract

    Ghione, P.; Cordeiro, P. G.; Ni, A.; Hu, Q.; Ganesan, N.; Galasso, N.; Dogan, A.; Horwitz, S. M.
    Hematological Oncology (2019)

    Fulltext@MSK | Save